Diabetes Care 48(1):S207-38 Marx N, Federici M, Schtt K, Mller-Wieland D, Ajjan RA, Antunes MJ et al (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)
Diarrhea occurs in approximately 30% of patients taking semaglutide 2.4 mg (Wegovy) and 19-23% of patients taking tirzepatide (Zepbound) according to FDA prescribing information
Improved Metabolic Function : Beyond blood sugar control, semaglutide helps regulate other aspects of metabolic health, such as lowering triglyceride levels and improving insulin sensitivity
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (familiar brand names include Jardiance, Farxiga, Ozempic, Wegovy, Mounjaro, Zepbound, Victoza ) are increasingly popular options, not only for glycemic control among patients with diabetes, but also for heart failure management and weight losseven in non-diabetics
Both medications can also cause less common but more serious issues, such as pancreatitis